{
    "nct_id": "NCT06077877",
    "official_title": "A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Expansion Study of the Oral DNA Polymerase Theta Inhibitor (POLQi) GSK4524101 and the PARP Inhibitor (PARPi) Niraparib in Adult Participants With Solid Tumors",
    "inclusion_criteria": "* More than or equal to (≥)18 years of age\n* Eastern cooperative oncology group (ECOG) class 0-2\n* Life expectancy of a minimum of 3 month\n* Participant has histologically diagnosed advanced or metastatic solid tumor and has exhausted all standard of care treatment options.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Participant has not recovered (i.e., to Grade less than or equal to [≤1] or to baseline) from prior chemotherapy-induced AEs.\n* Participant is currently participating in a treatment study or has participated in a study of any investigational agent within 4 weeks of the first dose of treatment.\n* Participant has symptomatic uncontrolled brain or leptomeningeal metastases.\n* Participant has a known additional malignancy that progressed or required active treatment within the last 2 years\n* Participant has a known history of Myelodysplastic syndrome (MDS) or Acute myeloid leukemia (AML).\n* Participant has uncontrolled hypertension with sustained systolic blood pressure (BP) >140 millimetres of mercury (mmHg) or diastolic BP >90 mmHg.",
    "miscellaneous_criteria": ""
}